Can we use a simple blood test to reduce patients who will receive neoadjuvant chemoradiation by timely identification of radiotherapy-resistant rectal cancers?

Can we use a simple blood test to reduce patients who will receive neoadjuvant chemoradiation by timely identification of radiotherapy-resistant rectal cancers? - MeD-Seq Rectal

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON53879

Enrollment

Registered

2022-11-17

Start date

2024-03-29

Completion date

Unknown

Last updated

2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal malignancy Rectal cancer

Interventions

Med Seq analysis

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age >18 - Histologically confirmed rectal adenocarcinoma - Scheduled for neoadjuvant chemoradiation

Exclusion criteria

Exclusion criteria: - Scheduled to another neoadjuvant schedule that comprises systemic chemotherapy or short-course radiation - Not able to read or understand Dutch language or mentally incompetent.

Design outcomes

Primary

Measure	Time frame
Pathological response rate (percentage necrosis in comparison to tumour cells in the resected specimen) after CRT, determined by an expert pathologist according to the Mandard Tumour Regression Grade (TRG).	—

Secondary

Measure	Time frame
cfDNA methylation profiling and molecular characteristics of the tumour tissue. Clinical features and molecular characteristics of patients with a clinical complete reponse. The analyses of this tissue will be as described above for the other tissue but this group will be investigated separately.	—

Countries

Netherlands

Contacts

Public ContactC. Verhoef

Erasmus MC, Universitair Medisch Centrum Rotterdam

c.verhoef@erasmusmc.nl0031 (0)10 7041902

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jul 23, 2026